Trade

with

Repros Therapeutics Inc
(NASDAQ: RPRX)
AdChoices
6.50
+0.28
+4.50%
After Hours :
6.50
0.00
0.00%

Open

6.15

Previous Close

6.22

Volume (Avg)

708.83k (1.17M)

Day's Range

6.14-6.55

52Wk Range

5.92-22.57

Market Cap.

143.74M

Dividend Rate ( Yield )

-

Beta

0.91

Shares Outstanding

23.11M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 9.00k

    • Net Income

    • -27.72M

    • Market Cap.

    • 143.74M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -253,266.67

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.91

    • Forward P/E

    • -3.80

    • Price/Sales

    • 10,000.00

    • Price/Book Value

    • 2.50

    • Price/Cash flow

    • -5.45

      • EBITDA

      • -27.46M

      • Return on Capital %

      • -39.24

      • Return on Equity %

      • -41.38

      • Return on Assets %

      • -39.24

      • Book Value/Share

      • 2.60

      • Shares Outstanding

      • 23.11M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 41.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.63

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 100.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -53.92

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -253,266.67

            • 39.38

            • Net Profit Margin

            • -253,266.67

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -308,840.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 14.94

              • 2.92

              • Quick Ratio

              • 14.85

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.07

              • 2.21

              • Book Value/Share

              • 2.60

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.73

                • 217.39

                • P/E Ratio 5-Year High

                • -22.60

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.84

                • 124.82

                • Price/Sales Ratio

                • 10,000.00

                • 9.52

                • Price/Book Value

                • 2.39

                • 8.61

                • Price/Cash Flow Ratio

                • -5.45

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -41.38

                        (-219.80)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -39.24

                        (-148.30)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -41.38

                        (-219.80)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -27.72M
                      Operating Margin
                      -308,011.11
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -5.45
                      Ownership

                      Institutional Ownership

                      96.07%

                      Top 10 Institutions

                      63.38%

                      Mutual Fund Ownership

                      28.54%

                      Float

                      87.56%

                      5% / Insider Ownership

                      0.75%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Biotechnology Discovery

                      •  

                        1,668,600

                      • 72.80

                      • 7.22

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        746,225

                      • 0.00

                      • 2.03

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        717,300

                      • 0.00

                      • 3.10

                      • Janus Global Life Sciences Fund

                      •  

                        653,542

                      • 3.19

                      • 2.83

                      • Vanguard Total Stock Mkt Idx

                      •  

                        350,577

                      • 0.00

                      • 1.52

                      • iShares Russell 2000 (AU)

                      •  

                        342,918

                      • -1.46

                      • 0.93

                      • Invesco Global Health Care Fd

                      •  

                        266,788

                      • 0.00

                      • 1.14

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        211,800

                      • 0.00

                      • 0.92

                      • Vanguard Extended Market Index Fund

                      •  

                        203,186

                      • 0.00

                      • 0.88

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Baker Bros Advisors LLC

                      •  

                        2,778,654

                      • 0.00%

                      • 12.02

                      • Visium Asset Management LLC

                      •  

                        1,840,799

                      • 0.00%

                      • 7.97

                      • Oracle Investment Management Inc

                      •  

                        1,267,126

                      • +2.00%

                      • 5.48

                      • RA Capital Management, LLC

                      •  

                        1,219,381

                      • -15.26%

                      • 5.28

                      • Sarissa Capital Management LP

                      •  

                        1,003,367

                      • +78.98%

                      • 4.34

                      • State Street Corp

                      •  

                        921,128

                      • -15.23%

                      • 3.99

                      • Partner Fund Management LP

                      •  

                        850,942

                      • -23.65%

                      • 3.68

                      • BlackRock Fund Advisors

                      •  

                        801,995

                      • +0.48%

                      • 3.47

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main pr...moreoduct candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company’s second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fi...morebroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.lessless

                      Key People

                      Joseph S. Podolski

                      CEO/Director/President

                      Nola E. Masterson,PhD

                      Chairman of the Board/Director

                      Ms. Katherine A. Anderson

                      CFO/Chief Accounting Officer/Secretary

                      Dr. Ronald Wiehle,PhD

                      Vice President, Divisional

                      Daniel F. Cain

                      Director

                      • Repros Therapeutics Inc

                      • 2408 Timberloch Place

                      • The Woodlands, TX 77380

                      • USA.Map

                      • Phone: +1 281 719-3400

                      • Fax: +1 281 719-3446

                      • reprosrx.com

                      Incorporated

                      1987

                      Employees

                      28

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: